source
- US biotech M&A surges as Chinese licensing deals dominate 2026 marketLocust Walk reports that China now accounts for 58% of global licensing deal value in 2026, while the United States share has dropped to 26%. Despite the licensing shift, US biotech companies are…
- Lilly advances retatrutide toward sleep-apnea marketEli Lilly is moving its triple-agonist drug retatrutide closer to a potential launch for sleep-apnea. The company, which expects to introduce the drug for obesity next year, is now gathering data i…